Mounjaro and pregnancy: what the FDA label §8.1 says and the preconception washout question

The Mounjaro FDA label Section 8.1 Pregnancy states human data are insufficient to evaluate for fetal risk and animal studies show fetal-growth reductions and malformations^[1]. The Section 12.3 elimination half-life is approximately 5 days; the textbook five-half-life washout convention is roughly 25 days — but the label does not specify a preconception interval^[1]. Every discontinuation decision belongs with your prescriber.

At a glance

• FDA Section 8.1 Pregnancy (Mounjaro): human data “insufficient to evaluate” for fetal risk; animal reproductive studies show malformations and fetal-growth reductions^[1].
• Label use language: MOUNJARO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus^[1].
• Half-life (FDA Section 12.3): approximately 5 days; clearance 0.061 L/h^[1].
• Five-half-life washout convention: roughly 25 days for tirzepatide as a textbook rule of thumb (label specifies no preconception interval)^[1].
• Birth-control absorption warning (Section 8.3): oral hormonal contraceptives may be less effective; switch to non-oral or add barrier for 4 weeks after initiation and 4 weeks after each dose escalation^[1].
• Periconceptional cohort data: two 2026 nationwide registries (Hviid Denmark, Chou Taiwan) examined obstetric outcomes after unintentional periconceptional GLP-1 exposure; neither identified a clear-cut teratogenic signal, both deferred to individualized care^[2][3].
• Class consensus: Muller 2023 systematic review^[4], Abedi 2026 narrative review^[5], and the Filippi-Arriaga 2025 EASO Position Statement^[6] all describe human data as sparse and call for individualized prescriber decisions.

What the Mounjaro FDA label Section 8.1 Pregnancy says (verbatim)

From the Mounjaro prescribing information, DailyMed SetID d2d7da5d-ad07-4228-955f-cf7e355c8cc0, Section 8.1 Pregnancy, Risk Summary^[1]:

Available data with MOUNJARO use in pregnant women are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations). Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy. MOUNJARO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

The label then anchors the background risk for the indicated population^[1]:

The estimated background risk of major birth defects is 6–10% in women with pre-gestational diabetes with an HbA1c >7% and has been reported to be as high as 20–25% in women with an HbA1c >10%. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively.

Three things to read carefully. First, the label does not say Mounjaro is contraindicated in pregnancy. It says human data are insufficient to evaluate. Those are different statements with different implications. Second, the elevated baseline major-birth-defect rate in women with pre-gestational diabetes (6–10% at A1c >7%, up to 20–25% at A1c >10%) is part of why “just stop the drug immediately” is not always the right answer for a person with type-2 diabetes — uncontrolled diabetes is itself a fetal-risk factor. Third, the entire risk-benefit weighing is explicitly handed to the prescriber.

The animal-data subsection (verbatim)

From Section 8.1 Animal Data^[1]:

In pregnant rats given twice weekly subcutaneous doses of 0.02, 0.1, and 0.5 mg/kg tirzepatide (0.03-, 0.07-, and 0.5-fold the MRHD of 15 mg once weekly based on AUC) during organogenesis, increased incidences of external, visceral, and skeletal malformations, increased incidences of visceral and skeletal developmental variations, and decreased fetal weights coincided with pharmacologically-mediated reductions in maternal body weights and food consumption at 0.5 mg/kg. In pregnant rabbits given once weekly subcutaneous doses of 0.01, 0.03, or 0.1 mg/kg tirzepatide (0.01-, 0.06-, and 0.2-fold the MRHD) during organogenesis, pharmacologically-mediated effects on the gastrointestinal system resulting in maternal mortality or abortion in a few rabbits occurred at all dose levels. Reduced fetal weights associated with decreased maternal food consumption and body weights were observed at 0.1 mg/kg.

Animal data are not human data, and the FDA notes the rat findings “coincided with pharmacologically-mediated reductions in maternal body weights and food consumption” — i.e., a fetus exposed to tirzepatide is also exposed to a mother who is eating substantially less. That is part of why the human extrapolation is uncertain. It is also part of why the label does not dismiss the animal findings: the rabbit effects were seen at 0.01-fold of human exposure, well below therapeutic dosing.

What Section 12.3 Pharmacokinetics tells us about washout timing

The Mounjaro Section 12.3 reports the apparent population mean clearance of tirzepatide is 0.061 L/h with an elimination half-life of approximately 5 days, enabling once-weekly dosing^[1]. The Section 10 Overdosage paragraph reiterates that “a period of observation and treatment for these symptoms may be necessary, taking into account the half-life of tirzepatide of approximately 5 days”^[1].

The standard pharmacokinetic teaching for “fully cleared from the body” is approximately five half-lives (about 97% elimination), which puts tirzepatide washout at roughly 25 days after the last dose. For deeper background on what “in your system” means across the GLP-1 class, see our companion explainer: How long does a GLP-1 stay in your system — semaglutide, tirzepatide, and orforglipron.

The “X weeks before conception” question

Many GLP-1 prescribers verbally recommend pausing tirzepatide for roughly 1–2 months before trying to conceive, citing the ~5-day half-life and the five-half-life pharmacokinetic convention. That is a reasonable clinical extrapolation but it is not a number that appears in the Mounjaro Section 8.1 label. The label does not specify any preconception interval — it instead says MOUNJARO “should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”^[1]

For comparison, some other obesity-class medications have explicit preconception language in their labels (for example, labels with documented teratogenic mechanisms often include explicit pregnancy-prevention requirements). The Mounjaro and Zepbound labels do not use that kind of language^[7]. The asymmetry between “sparse human data” (Mounjaro/Zepbound) and “documented mechanism of harm” (e.g., isotretinoin, valproate) is part of why prescribers do not all converge on a single number of weeks.

Class-effect data: what the registries show

Hviid 2026 — Danish nationwide periconceptional cohort

Hviid and colleagues (2026, Human Reproduction Open, PMID 41852577) used Danish national health registries to examine obstetric outcomes after periconceptional GLP-1 receptor agonist exposure^[2]. The cohort design captures unintentional exposure — typically women who became pregnant while on a GLP-1, often because of the oral contraceptive absorption issue (see Section 8.3 above). The published analysis did not identify a clear-cut teratogenic signal at the cohort level. The authors caveated the limited sample size for specific outcomes and explicitly did not endorse intentional GLP-1 use during pregnancy.

Chou 2026 — Taiwan nationwide periconceptional cohort

Chou and colleagues (2026, Diabetes Obesity and Metabolism, PMID 41346258) used the Taiwan National Health Insurance Research Database to examine unintentional periconceptional GLP-1 exposure and adverse pregnancy outcomes^[3]. Like the Danish cohort, the design captures real-world unintentional exposure and the published findings did not produce a clear signal that overturns the Section 8.1 label framing. The authors emphasized the same individualized-care conclusion as the Danish team.

Muller 2023 systematic review and Abedi 2026 narrative review

Muller and colleagues (2023, Frontiers in Endocrinology, PMID 37881498) systematically reviewed GLP-1 and SGLT2 use in pregnancy and lactation and concluded the human evidence base is sparse and decisions must be individualized^[4]. Abedi and colleagues (2026, Journal of Clinical Medicine, PMID 42122936) narratively reviewed GLP-1s, fertility restoration, and reproductive safety in women of reproductive age and reached the same conclusion^[5]. Both papers also note the fertility-restoration angle: GLP-1-driven weight loss can restore ovulation in women with obesity-related anovulation (including PCOS), which is part of why unintentional pregnancy on a GLP-1 is a recurring clinical scenario — see our deeper GLP-1s, pregnancy, PCOS, and fertility guide.

Filippi-Arriaga 2025 EASO Position Statement

The European Association for the Study of Obesity 2025 Position Statement on women with obesity across the reproductive life (Filippi-Arriaga 2025, Obesity Facts, PMID 40544836)^[6] calls for prospective preconception, pregnancy, postpartum, and breastfeeding registries to close the GLP-1 evidence gap. EASO does not endorse intentional GLP-1 use during pregnancy and frames preconception discontinuation as a shared decision with the prescribing clinician.

Birth control absorption and the tirzepatide exception

One reason periconceptional exposure happens at all is that tirzepatide specifically is labeled with an oral-contraceptive absorption warning. From Mounjaro Section 8.3^[1]:

Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO.

This 4-week-after-initiation + 4-week-after-each-escalation window is unique to tirzepatide among the injectable GLP-1s — semaglutide labels do not carry the same explicit oral contraceptive instruction. For the full breakdown of what the backup-contraception rule actually means in practice, see our dedicated article: The Mounjaro and Zepbound birth control warning — what the FDA label actually says.

The Zepbound comparator

Zepbound and Mounjaro are both tirzepatide (DailyMed Zepbound SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b)^[7]. The Zepbound Section 8.1 Pregnancy uses similar Risk Summary language and the same animal-data findings as the Mounjaro label, because the molecule is identical. The obesity indication for Zepbound and the type-2-diabetes indication for Mounjaro are managed under separate trade names but the preconception pharmacology — the approximately 5-day half-life, the theoretical 25-day five-half-life washout, the fetal-growth animal findings — applies to both.

Practical questions to bring to your prescriber

If you are on Mounjaro and considering pregnancy — or if you have just learned you are pregnant while on Mounjaro — these are reasonable conversation prompts. They are questions to ask, not answers we are providing.

• What is my clinical indication and how urgent is staying on Mounjaro versus pausing it for the conception attempt?
• Given the approximately 5-day half-life, what preconception washout interval do you recommend in my case?
• Is there a non-GLP-1 alternative for my indication that is more compatible with conception attempts?
• For type-2 diabetes specifically, would insulin or metformin be reasonable bridge therapy while we try to conceive?
• What A1c target should we be at before stopping Mounjaro?
• What contraception plan should I use during the washout period so the timing is intentional?
• If I conceive while still on Mounjaro, what would the next steps be and who should I see?
• For ongoing pregnancy monitoring, would you involve a maternal-fetal medicine specialist?

How this fits with the rest of the Mounjaro reproductive safety picture

Three companion articles cover the rest of the Mounjaro reproductive-safety surface:

• Mounjaro and breastfeeding — what the FDA label §8.2 Lactation actually says covers the n=11 single-dose human-milk pharmacokinetic study and the postpartum decision framework.
• The Mounjaro and Zepbound birth control warning breaks down the Section 8.3 oral-contraceptive absorption rule and the 4-week backup-contraception window unique to tirzepatide.
• GLP-1s in pregnancy, PCOS, and fertility covers the broader class-level evidence base and the fertility-restoration mechanism that makes unintentional GLP-1 pregnancy a recurring clinical scenario.
• The “Ozempic baby” fertility and pregnancy evidence review walks the comparator semaglutide reproductive data and the underlying ovulation-restoration mechanism.

Bottom line

The Mounjaro FDA label Section 8.1 Pregnancy says human data are insufficient to evaluate fetal risk, animal studies show fetal-growth reductions and malformations, and MOUNJARO should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus^[1]. The Section 12.3 elimination half-life is approximately 5 days and the textbook five-half-life washout convention is roughly 25 days — but the label does not specify a preconception interval^[1]. The published periconceptional cohort data from Denmark^[2] and Taiwan^[3] did not identify a clear teratogenic signal but were not designed to endorse intentional use. The Muller 2023 systematic review^[4], the Abedi 2026 narrative review^[5], and the EASO 2025 Position Statement^[6] all describe the human evidence base as sparse and call for individualized prescriber decisions. We do not tell you when to stop Mounjaro before trying to conceive. We tell you what the label says, what the published cohort and review evidence shows, and we ask you to bring those facts to the clinician who knows your indication, your A1c, and your full reproductive plan.

Editorial note. All clinical claims in this article were verified live on 2026-05-25. The Mounjaro Section 8.1, 8.3, and 12.3 quotes were taken directly from the DailyMed-hosted FDA prescribing information (SetID d2d7da5d-ad07-4228-955f-cf7e355c8cc0); the Zepbound comparator label was verified via DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b. The five PubMed-indexed references (Hviid 2026 PMID 41852577; Chou 2026 PMID 41346258; Muller 2023 PMID 37881498; Abedi 2026 PMID 42122936; Filippi-Arriaga 2025 PMID 40544836) were verified via the NCBI esummary API on the publication date. No PMIDs are stated for claims they do not support; no preconception washout interval is recommended in this article because the FDA Mounjaro label does not specify one.